Please assess the completion status of the following clinical trial:

Trial Title: Timing and Duration of Acute Hepatitis C Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age: 18-50 years, with or without symptoms~* Diagnosis of acute hepatitis C: elevated serum alanine aminotransferase (ALT) \> 10 times the upper limit of normal (ULN)~* Seroconversion from negative to positive anti-HCV antibody status (third-generation enzyme-linked immunosorbent assay)~* Conversion from negative to positive polymerase chain reaction (PCR) for HCV-RNA, ruling out other causes of hepatitis by history and appropriate serologic and virologic studies.~Exclusion Criteria:~* Decompensated liver disease~* Coinfection with human immunodeficiency virus (HIV) or Schistosoma mansoni~* Marked anemia (hemoglobin level ≤ 120 g/L in women and ≤ 130 g/L in men)~* Neutropenia (\< 1,500/mm3)~* Thrombocytopenia (\< 90,000/mm3)~* A creatinine concentration \> 1.5 times ULN~* Serum alpha-fetoprotein \> 25 ng/ml~* An organ transplant~* Neoplastic disease~* Severe cardiac or pulmonary disease~* Unstable thyroid dysfunction~* A psychiatric disorder~* Seizure disorder~* Severe retinopathy~* A current pregnancy or were breast feeding or unwillingness to practice contraception~* Therapy with immunomodulatory agents within the last 6 months~* Alcohol or drug dependence within 1 year of study entry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).